> top > projects > Inflammaging > docs > PubMed:32352535 > annotations
Inflammaging  

PubMed:32352535 JSONTXT 3 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T1 0-107 Sentence denotes COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.
T1 0-107 Sentence denotes COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.
T2 108-234 Sentence denotes The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades.
T2 108-234 Sentence denotes The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades.
T3 235-376 Sentence denotes We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies.
T3 235-376 Sentence denotes We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies.
T4 377-581 Sentence denotes While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system.
T4 377-581 Sentence denotes While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system.
T5 582-662 Sentence denotes Risk of severe infection and mortality increase with advancing age and male sex.
T5 582-662 Sentence denotes Risk of severe infection and mortality increase with advancing age and male sex.
T6 663-790 Sentence denotes Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer.
T6 663-790 Sentence denotes Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer.
T7 791-1126 Sentence denotes The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC).
T7 791-1126 Sentence denotes The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC).
T8 1127-1397 Sentence denotes Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) -a homologue of ACE-to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes.
T8 1127-1397 Sentence denotes Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) -a homologue of ACE-to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes.
T9 1398-1553 Sentence denotes This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI).
T9 1398-1553 Sentence denotes This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI).
T10 1554-1696 Sentence denotes While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis.
T10 1554-1696 Sentence denotes While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis.
T11 1697-1746 Sentence denotes Hence, patients should not discontinue their use.
T11 1697-1746 Sentence denotes Hence, patients should not discontinue their use.
T12 1747-1844 Sentence denotes Moreover, renin-angiotensin-aldosterone system (RAAS) inhibitors might be beneficial in COVID-19.
T12 1747-1844 Sentence denotes Moreover, renin-angiotensin-aldosterone system (RAAS) inhibitors might be beneficial in COVID-19.
T13 1845-2012 Sentence denotes Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19.
T13 1845-2012 Sentence denotes Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19.
T14 2013-2219 Sentence denotes Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications.
T14 2013-2219 Sentence denotes Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications.
T15 2220-2315 Sentence denotes Preventive measures (social distancing and social isolation) also increase cardiovascular risk.
T15 2220-2315 Sentence denotes Preventive measures (social distancing and social isolation) also increase cardiovascular risk.
T16 2316-2582 Sentence denotes Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.
T16 2316-2582 Sentence denotes Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.